UPDATE: Benchmark Raises PT to $20 on Exact Sciences Corporation Ahead of Top Line Data
Benchmark maintained Exact Sciences Corporation (NASDAQ: EXAS ) with a Speculative Buy and raised the price target from $17.00 to $20.00. Benchmnark noted, "Exact's Q4 update affirmed our expectation that pivotal top line colorectal cancer study data should be announced in March or April. These results are expected to
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here